Smithkline Beecham Corporation

Affinium Pharmaceuticals, Inc.

Glaxo Group Limited

Peter Henry Milner

Andrew Faller

David John Payne

Stewart Campbell Pearson

John Timothy Lonsdale

Steven James Stanway

David Timothy Macpherson

Alan Naylor

Emmanuel Hubert Demont

David Robert Vesey

Daryl Simon Walter

John Gerard Ward

David Timothy MacPherson

John Gerald Ward

Sally Redshaw

Leontine Saskia Trouw

Jayshree Mistry

The present invention relates to novel hydroxyethylamine compounds having Asp2 (&#x3b2;-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits, particularly Alzheimer's disease.

Hydroxyethylamine derivatives for the treatment of Alzheimer's disease

The present invention relates to novel hydroxyethylene compounds having Asp2 (&#x3b2;-secretase. BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits, particularly Alzheimer's disease.

Hydroxyethylene compounds with Asp2 inhibitory activity

Prokayrotic FAB I polypeptides and DNA (RNA) encoding such FAB I and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FAB I for the treatment of infection, such as bacterial infections. Antagonists against such FAB I and their use as a therapeutic to treat infections, such as staphylococcal infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of FAB I nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding FAB I and for detecting the polypeptide in a host.

[object Object]

The present invention relates to novel hydroxyethylene compounds having Asp2 (&#x3b2;-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits, particularly Alzheimer's disease.

Benzamide derivatives, processes for their preparation, and their pharmaceutical use

Prokayrotic FABI polypeptides and DNA (RNA) encoding such FABI and a procedure for such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FABI for the treatment of infection, such as bacterial infections. Antagonists against such FABI and their use as a therapeutic to treat infections, such asstaphylococcal infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of FABI nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding FABI and for detecting the polypeptide in a host.

FabI

Compounds of Formula (1) wherein: R is methyl substituted by one to three groups from alkyl, aryl, alkenyl, and alkynyl; n is ) or 1; R is arylmethyl or heterocyclylmethyl; R is alkyl, alkenyl, cycloalkyl or cycloalkenyl; and R is hydrogen, alkyl, alkenyl, alkynyl or aryl; are useful in the treatment of disorders mediated y s-CD23.

Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release

Prokayrotic FAB I polypeptides and DNA (RNA) encoding such FAB I and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FAB I for the treatment of infection, such as bacterial infections. Antagonists against such FAB I and their use as a therapeutic to treat infections, such asstaphylococcal infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of FAB I nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding FAB I and for detecting the polypeptide in a host.

Growing community of inventors

Harlow, United Kingdom

Peter Henry Milner